Compare · CELZ vs SPGI
CELZ vs SPGI
Side-by-side comparison of Creative Medical Technology Holdings Inc. (CELZ) and S&P Global Inc. (SPGI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CELZ and SPGI operate in Finance: Consumer Services (Finance), so they compete in similar markets.
- SPGI is the larger of the two at $123.46B, about 15394.7x CELZ ($8.0M).
- Over the past year, CELZ is down 17.1% and SPGI is down 18.4% - CELZ leads by 1.3 points.
- SPGI has hit the wire 29 times in the past 4 weeks while CELZ has been quiet.
- SPGI has more recent analyst coverage (25 ratings vs 1 for CELZ).
- Company
- Creative Medical Technology Holdings Inc.
- S&P Global Inc.
- Price
- $2.08-4.59%
- $420.31+0.73%
- Market cap
- $8.0M
- $123.46B
- 1M return
- -6.73%
- +0.09%
- 1Y return
- -17.13%
- -18.41%
- Industry
- Finance: Consumer Services
- Finance: Consumer Services
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 0
- 29
- Recent ratings
- 1
- 25
Creative Medical Technology Holdings Inc.
Creative Medical Technology Holdings, Inc., a biotechnology company, focuses on immunology, urology, orthopedics, and neurology using adult stem cell treatments. The company offers CaverStem for the treatment of erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; StemSpine for the treatment of chronic lower back pain; Amniostem for the treatment of strokes, radiation, toxicity, and glioma; ImmCelz for the treatment of stroke patients; and OvaStem for treatment of female infertility. Creative Medical Technology Holdings, Inc. was incorporated in 1998 and is based in Phoenix, Arizona.
S&P Global Inc.
S&P Global Inc., together with its subsidiaries, provides ratings, benchmarks, analytics, and data to the capital and commodity markets worldwide. The company operates through four segments: S&P Global Ratings (Ratings), S&P Global Market Intelligence (Market Intelligence), S&P Global Platts (Platts), and S&P Dow Jones Indices (Indices). The Ratings segment offers credit ratings, research, and analytics to investors, corporations, governments, municipalities, commercial and investment banks, insurance companies, asset managers, and other debt issuers. The Market Intelligence segment provides multi-asset-class data, research, and analytical capabilities that integrate cross-asset analytics and desktop services to investment managers, investment banks, private equity firms, insurance companies, commercial banks, corporations, professional services firms, government agencies, and regulators. The Platts segment offers essential price data, analytics, and industry insights for the commodity and energy markets. It serves producers, traders, and intermediaries within the energy, petrochemicals, metals, and agriculture markets. The Indices segment provides index that maintains various valuation and index benchmarks for investment advisors, wealth managers, and institutional investors. The company also offers analytics, artificial intelligence, machine learning, and data visualization systems to Wall Street's premier global banks and investment institutions, as well as the National Security community; subscription and custom reports on bank deposits, loans, fees, and other product data to the financial services industry; and insights on global supply chains. The company was formerly known as McGraw Hill Financial, Inc. and changed its name to S&P Global Inc. in April 2016. S&P Global Inc. was founded in 1860 and is headquartered in New York, New York.
Latest CELZ
- SEC Form 10-Q filed by Creative Medical Technology Holdings Inc.
- Creative Medical Technology Holdings, Inc. Reports Breakthrough 93% Response Rate in Ultrasome™ Knee Osteoarthritis Program, Expanding CELZ-201 Platform into Scalable Cell-Free Regenerative Therapies
- Amendment: SEC Form 10-K/A filed by Creative Medical Technology Holdings Inc.
- SEC Form 10-K filed by Creative Medical Technology Holdings Inc.
- Creative Medical Technology Holdings Achieves Second WHO INN Milestone, Strengthening Global Regulatory Positioning Across Expanding Cell Therapy Pipeline
- Creative Medical Technology Holdings Reaches Major Clinical Inflection Point with Positive Interim Data from ADAPT Trial and CELZ-201 (Olastrocel) in the Treatment of Chronic Lower Back Pain
- Creative Medical Technology Holdings Receives Regulatory Approval for BioDefense Burn Pit Initiative
- Creative Medical Technology Holdings Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Creative Medical Technology Holdings Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Creative Medical Technology Holdings, Inc. Completes Enrollment in FDA-Cleared ADAPT Trial for CELZ-201-Olastrocel, Marking Major Clinical Inflection Point
Latest SPGI
- Sirius XM Holdings Set to Join S&P MidCap 400
- S&P Global Expands AI Ecosystem Reach with Cohere to Power Trusted, Agentic Workflows for Financial Institutions
- Marvell Technology and Flex Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600
- S&P Global to Present at Mizuho Technology Conference 2026 on June 10, 2026
- S&P Dow Jones Indices Announces Changes to the S&P/TSX Composite Index
- S&P Dow Jones Indices Consultation on Treatment of MegaCap Companies - Results
- S&P Global Launches Agentic AI-Powered Credit Memo Builder™ to Streamline Credit Analysis
- American Business Bank Ranked 6th in Top 50 Community Banks With Assets Between $3 Billion and $10 Billion for 2025
- ION Commodities expands collaboration with S&P Global Energy Platts
- FedEx Freight Holding Set to Join Dow Jones Transportation Average